‘Fairness': Major change outlaws ticketless parking fines in NSW
The Minns Labor government has announced a return to ticketed parking fines, ending what it refers to as 'years of an unfair system', where drivers could be issued a parking fine but not be notified until weeks after the offence.
The ticketless system was implemented by the Coalition in 2020, and quickly saw a significant rise in the number of fines issued.
The reforms will reinstate the old-school on-the-spot ticketing system which will require parking officers to physically attach a parking fine or notification to the vehicle.
There will also be a requirement for the driver of the vehicle to be notified of the fine no longer than seven days after the offence takes place.
NSW Finance Minister Courtney Houssos said the new system would ensure people would no longer be 'caught by a surprise parking ticket weeks later'.
'Our commonsense changes bring fairness and transparency back to the system' she said.
'Motorists will once again benefit from on-the-spot notifications. New requirements that motorists are provided with photos of the offence will assist them if they wish to object to a fine.'
NRMA Spokesperson Peter Khoury said the organisation welcomed the removal of ticketless parking fines in NSW, and commended the state government 'for listening to motorists and making this commonsense reform'.
'Transparency matters. People deserve to know when and why they're being fined – and to have a fair chance to challenge if needed,' he said.
'The Government has worked through the issues, consulted widely, and come to an appropriate solution. Today is a great day for NSW motorists.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
23 minutes ago
- News.com.au
Top 10 at 11: ASX jumps on open as copper and battery metals rally
Morning, and welcome to Stockhead's Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earnest. In brief, this is what the market has been up to this morning. Resources drive early gains The ASX 200 has jumped 0.42% in the first half hour of trading, with 9 of 11 sectors making gains as of about 10:30 am AEST. The materials sector is leading the charge, building on momentum generated by a rally in lithium and battery metal stocks and a 5.9% jump in James Hardie (ASX:JHX) shares. The construction materials company completed its acquisition of NYSE-listed outdoor living business AZEK today, adding to its extensive portfolio of exterior design brands. Lithium, rare earth and copper stocks are making the biggest moves this morning, including several of the stocks on our small cap winners list… WINNERS Code Name Last % Change Volume Market Cap PKO Peako Limited 0.003 50% 120000 $2,975,484 EEL Enrg Elements Ltd 0.002 33% 792525 $4,880,668 IS3 I Synergy Group Ltd 0.002 33% 620409 $2,253,285 SRN Surefire Rescs NL 0.002 33% 1500000 $3,729,668 LAT Latitude 66 Limited 0.029 26% 10932 $3,298,216 ADG Adelong Gold Limited 0.005 25% 60000 $8,274,707 DY6 Dy6Metalsltd 0.145 23% 1246772 $8,749,344 HOR Horseshoe Metals Ltd 0.025 19% 670720 $14,070,141 BCA Black Canyon Limited 0.16 19% 405899 $17,502,844 ID8 Identitii Limited 0.007 17% 15000 $4,668,081 In the news... Horseshoe Metals (ASX:HOR) is preparing to fire up its direct shipping ore operations for the Horseshoe Lights copper-gold project in WA, after getting the greenlight from the DEMIRS. HOR expects to have boots on the ground within the next few weeks, with sales of existing copper stockpiles to begin shortly thereafter. It's perfect timing for the company, with the price of copper soaring more than 26% in the year to date to reach 10-year highs. Latitude 66 (ASX:LAT) is offloading its 17.5% interest in the Greater Duchess joint venture project, triggering a right of first refusal for JV partner Carnaby Resources (ASX:CNB). LAT is looking to sell its interest for $2m, with some conditional payments on the table of up to $4m in cash or ASX-listed shares. If the project is sold within 90 days of the sale and anyone can get their hands on 100% of the project interest, LAT will be $4m richer; if only a partial sale is made in that time, the company will earn 50% of any proceeds above $4m. LAGGARDS Code Name Last % Change Volume Market Cap AOA Ausmon Resorces 0.001 -50% 111800 $2,622,427 VHL Vitasora Health Ltd 0.03 -23% 3864299 $61,504,061 MMR Mec Resources 0.004 -20% 504034 $9,248,829 PIL Peppermint Inv Ltd 0.002 -20% 100000 $5,752,724 C29 C29Metalslimited 0.015 -17% 1772692 $3,135,388 CUS Coppersearchlimited 0.016 -16% 100593 $3,018,941 RDS Redstone Resources 0.003 -14% 150000 $3,619,936 RNX Renegade Exploration 0.0035 -13% 616666 $5,153,454 CPV Clearvue Technologie 0.14 -13% 368291 $42,980,027 NYM Narryermetalslimited 0.031 -11% 101959 $6,161,918
News.com.au
23 minutes ago
- News.com.au
Health Check: Like bloodthirsty sharks, offshore acquirers are circling cheap biotech assets
As today's Medadvisor deal attests, underperforming biotech assets are getting a bite or two Next Science shares continue to rally, but the company is still valued at less than Demant's offer price for most of its assets Neurizon enters a key deal with the supplier of its drug candidate for motor neurone disease Inspired by the 50 th anniversary of the original Jaws movie, local and offshore predators are on the hunt for local biotech prey. Today, medication compliance group MedAdvisor (ASX:MDR) said it had entered a binding agreement to sell its Australian ops to the Canadian owned Jonas Software, for a headline $35 million. As we reported yesterday, Medadvisor was the worst performing ASX-listed biotech last financial year, sinking 82%. Yesterday, struggling wound management company Next Science (ASX:NXS) proposed a US$50 million ($75 million) deal to sell most of its assets. The buyer is the Milan based Demetra Holdings (see below). Mayne Pharma (ASX:MYX) is – or was – subject to a $600 million offer from US dermatology group Cosette, but the suitor spat out the arm after due diligence (allegedly) revealed horrors lurking in depths. As with the makers of the epic Jaws movie, we must apologise to the sea's apex predators for besmirching their reputation. Unlike with the six remarkably careless Jaws 1 victims, biotech's metaphorical equivalent is usually most welcome. Medadvisor prefers US focus Coming back to Medadvisor, the company wants to focus on its bigger US business, which provides prescription drug information services to patients via big pharma and chemists. The terms are like the non-binding ones announced on May 9. One quirk is that the deal includes the Medadvisor moniker, but Medadvisor can continue to use that name under a royalty-free arrangement. Still, the company will seek shareholder approval to change its name. While Medadvisor pockets $35 million now, it has dibs on an 'uncapped contingent consideration' based on the divested arm's performance. On current trends, the company would expect another $7.35 million. Medadvisor intends to use some of the proceeds to discharge a $23.5 million finance facility. The company will use the remainder pending a review of its US operations, which have been hit by a downturn in vaccination rates. This has resulted in the jab makers winding back promotional spend. Next Science investors retain zeal for deal Having pushed up Next Science shares 64% yesterday, investors today added another 9% on the back of the proposal that in effect will see their company disappear. The proposal is subject to the consent of Next Science shareholders at a meeting scheduled on August 14. In framing the friendly deal, Demetra no doubt has chatted to Next Science's 37% shareholder, property tycoon and biotech dabbler Lang Walker. The deal is also subject to an independent expert report. Next Science intends to redistribute to shareholders the estimated US$30 million remaining after winding up costs. With approved products in the US, Next Science operates in wound care and surgical infection control. Demetra supplies bone cement, for fixing orthopaedic implants and the like. Next Science's regally dubbed CEO, Harry Hall IV says that in Demetra's more capacious hands Next Science's products 'will be better positioned to realise their full potential in improving patient care globally'. Next Science listed at $1 in April 2019 in a $35 million IPO and peaked at close to $2 in mid 2021. It's been downhill from there. Meanwhile the ASX circle of life continues, with wound management house Tetratherix (ASX:TTX) listing successfully last Monday. Interestingly, Next Science still bears a market cap of a mere $34 million. Neurizon does 'vet' deal but it's not going to the dogs The developer of a repurposed drug candidate for a form of motor neurone disease, Neurizon Therapeutics (ASX:NUZ) has entered an exclusive global licensing agreement with the New York-listed Elanco Animal Health. The deal doesn't take Neurizon back into veterinary drugs, the company's key remit when it was known as Pharmaust. But Elanco is the exclusive maker of the drug candidate – monepantel – which regulators originally approved as a sheep drench. Monepantel is the active component of NUZ-001, Neurizon's lead therapy for amyotrophic lateral sclerosis (ALS) and other human neurodegenerative diseases. The deal bestows Neurizon with the global rights for Elanco's intellectual property, including extensive non-clinical (animal) and manufacturing data. The agreement also outlines key terms for Elanco's future supply of monepantel, with a formal agreement expected in the current half. Monepantel works by inhibiting the mTOR signalling pathway, which plays a central role in the growth of cancer cells and the degeneration of neurons. mTOR stands for the 'mechanistic Target of Rapamycin', a reference not to a Tolkien novel but a well-known oncology target (rapamycin). Neurizon is participating in Healey ALS, a collaborative MND trial across 70-plus sites in the US. The platform will test several drugs simultaneously, thus increasing patient access and reducing study costs and completion and enrolment times. Neurizon CEO Dr Michael Thurn says the deal should 'dramatically reduce near-term development costs and accelerate development timelines.' The deal involves a nominal up-front payment and back-ended development milestones of US$9.75 million for the initial product. Should sales take off, Neurizon pays sales milestones of up to US$65 million but we'll cross that bridge when we come to it. Emvision's Emu hops to five sites, with one more to come The developer of a portable bedside stroke scanner dubbed Emu, EMvision Medical Devices (ASX:EMV) hopes to sign up its sixth and final site for its pivotal trial pitched at regulatory approval. The company today said five sites – three in the US and two locally – were now 'actively enrolling and scanning patients'. The three US sites are New York's Mt Sinai Hospital, Florida's Mayo Clinic and UT Health Memorial Hermann Texas Medical Centre. The local sites are Royal Melbourne Hospital and Sydney's Liverpool Hospital. The sixth site, at a west coast US clinic, should be announced 'shortly'. Emvision also won assent to start a continuous innovation study for stroke and traumatic brain injury patients, at Newcastle's John Hunter Hospital and Brisbane's Princess Alexandra Hospital. The trial involves enrolling up to 300 suspected stroke victims. Clinicians will assess them in the normal manner along with an Emu scan. The study aims to determine accurately whether a stroke is a blood clot or a bleed. If Emu takes flight, the company plans to seek expedited US approval for an ambulance variant, called First Responder.
News.com.au
23 minutes ago
- News.com.au
Court rejects parliamentary privilege claim in Walter Sofronoff's bid to overturn corruption findings
Claims parliamentary privilege would prevent a report that found the head of an inquiry into the prosecution of Bruce Lehrmann engaged in 'serious corrupt conduct' from being tendered in court have been rejected by a court. Former Queensland judge Walter Sofronoff KC led the 2023 board of inquiry into Mr Lehrmann's prosecution. An investigation into Mr Sofronoff's conduct during that inquiry, in particular his decision to send a copy of the board's report to two journalists from the ABC and The Australian prior to its official release by the ACT government, was launched by the ACT Integrity Commission. The commission in March found Mr Sofronoff had engaged in 'serious corrupt conduct'; however, he is seeking to have the commission's Operation Juno report overturned in the Federal Court. Lawyers for the Speaker of the ACT Legislative Assembly in May submitted the proceedings should be dismissed over claims the report was covered by parliamentary privilege, meaning it couldn't be tendered in court. Therefore, the retired judge couldn't seek judicial review. Justice Wendy Abraham said she allowed the Speaker to make the submission but ultimately dismissed it on Wednesday morning during a brief case management hearing in the Federal Court. 'I am not satisfied that the conduct of the proceedings on the material on which the applicant seeks to rely involves an infringement of Section 16 of the Parliamentary Privilege Act,' Justice Abraham told the court. 'I'll provide reasons for that in my final judgment.' The matter is scheduled for a final hearing on July 21 and 22. Documents filed by his legal team claim that Mr Sofronoff was given the ability to do 'whatever (he) considers necessary or convenient for the fair and prompt conduct of the inquiry' as head of the inquiry, and he considered it necessary or convenient to engage with journalists 'for the fair and prompt conduct of the inquiry'. The documents also claim Mr Sofronoff's actions were 'incapable of amounting to corrupt conduct' and the findings were 'seriously illogical, irrational and/or unreasonable'. The Federal Court has found that Mr Lehrmann raped Ms Higgins on the civil standard of the balance of probabilities. A criminal trial was aborted due to juror misconduct and a charge against him was dropped. Mr Lehrmann has always denied the allegation and is appealing the Federal Court's finding.
